Illumina Shares Jump Amid Analyst Target Hikes
Illumina's stock surged 7.7% following price target increases from Wall Street analysts. The upgrades are attributed to expectations of improved clinical sales and new business catalysts.
7% in the afternoon session after Wall Street analysts raised their price targets on expectations for an improvement in clinical sales and new catalysts, as market participants increasingly viewed the company's gene-sequencing business more positively.